<DOC>
	<DOCNO>NCT00146159</DOCNO>
	<brief_summary>The purpose study show dose-response relationship three dose mitoxantrone regard efficacy patient secondary progressive multiple sclerosis show safety tolerability mitoxantrone patient .</brief_summary>
	<brief_title>Study Evaluating Mitoxantrone Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Secondary progressive MS active stage EDSS 3 6 Benign primary progressive MS Patients cardiac risk factor Patients already receive mitoxantrone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Multiple Sclerosis</keyword>
</DOC>